Key points are not available for this paper at this time.
Inhibition of matrix metalloproteinases (MMPs) as an approach to treatment of diseases such as cancer, arthritis and multiple sclerosis (MS) is now an area of intense interest within the pharmaceutical industry. This review summarises developments in the design and clinical evaluation of synthetic MMP inhibitors since the subject was last covered in this journal in 1996.
Beckett et al. (Sun,) studied this question.